The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
MRI detection of breast cancer micrometastases with a fibronectin-targeting contrast agent
Open accessAbstract
Metastasis is the primary cause of death in breast cancer patients. Early detection of high-risk breast cancer, including micrometastasis, is critical in tailoring appropriate and effective interventional therapies. Increased fibronectin expression, a hallmark of epithelial-to-mesenchymal transition, is associated with high-risk breast cancer and metastasis. We have previously developed a penta-peptide CREKA (Cys-Arg-Glu-Lys-Ala)-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agent, CREKA-Tris(Gd-DOTA)3 (Gd-DOTA (4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecyl gadolinium), which binds to fibrin–fibronectin complexes that are abundant in the tumour microenvironment of fast-growing breast cancer. Here we assess the capability of CREKA-Tris(Gd-DOTA)3 to detect micrometastasis with MRI in co-registration with high-resolution fluorescence cryo-imaging in female mice bearing metastatic 4T1 breast tumours. We find that CREKA-Tris(Gd-DOTA)3 provides robust contrast enhancement in the metastatic tumours and enables the detection of micrometastases of size <0.5 mm, extending the detection limit of the current clinical imaging modalities. These results demonstrate that molecular MRI with CREKA-Tris(Gd-DOTA)3 may facilitate early detection of high-risk breast cancer and micrometastasis in the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
A Perspective on Cancer Cell Metastasis
Chaffer, C. L., & Weinberg, R. A. (2011) · Science · doi:10.1126/science.1203543 · Cited by 4,807
The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited
Fidler, I. J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1098 · Cited by 4,686
Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications
Caravan, P., Ellison, J. J., McMurry, T. J., & Lauffer, R. B. (1999) · Chemical Reviews · doi:10.1021/cr980440x · Cited by 4,483
The extracellular matrix: A dynamic niche in cancer progression
Lu, P., Weaver, V. M., & Werb, Z. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201102147 · Cited by 3,024
Metastatic Behavior of Breast Cancer Subtypes
Kennecke, H., Yerushalmi, R., Woods, R., Cheang, M. C. U., Voduc, D., Speers, C. H., Nielsen, T. O., & Gelmon, K. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9820 · Cited by 2,262
Breast cancer metastasis: markers and models
Weigelt, B., Peterse, J. L., & van't Veer, L. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1670 · Cited by 2,232
Metastasis: a question of life or death
Mehlen, P., & Puisieux, A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1886 · Cited by 1,863
Genomic analysis of metastasis reveals an essential role for RhoC
Clark, E. A., Golub, T. R., Lander, E. S., & Hynes, R. O. (2000) · Nature · doi:10.1038/35020106 · Cited by 1,445
The clinical course of bone metastases from breast cancer
Coleman, R., & Rubens, R. (1987) · British Journal of Cancer · doi:10.1038/bjc.1987.13 · Cited by 1,084
Cited by
Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers
Wahsner, J., Gale, E. M., Rodríguez-Rodríguez, A., & Caravan, P. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00363 · Cited by 1,603
Theranostic Fluorescent Probes
Sharma, A., Verwilst, P., Li, M., Ma, D., Singh, N., Yoo, J., Kim, Y., Yang, Y., Zhu, J.-H., Huang, H., et al. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00778 · Cited by 499
Radiomics in breast cancer classification and prediction
Conti, A., Duggento, A., Indovina, I., Guerrisi, M., & Toschi, N. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.04.002 · Cited by 386
A framework for the development of effective anti-metastatic agents
Anderson, R. L., Balasas, T., Callaghan, J., Coombes, R. C., Evans, J., Hall, J. A., Kinrade, S., Jones, D., Jones, P. S., Jones, R., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0134-8 · Cited by 341
Systemic Review of Biodegradable Nanomaterials in Nanomedicine
Su, S., & Kang, P. M. (2020) · Nanomaterials · doi:10.3390/nano10040656 · Cited by 312
Cancer nanotechnology: current status and perspectives
Kemp, J. A., & Kwon, Y. J. (2021) · Nano Convergence · doi:10.1186/s40580-021-00282-7 · Cited by 266
Du, Y., Liu, X., Liang, Q., Liang, X.-J., & Tian, J. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b00630 · Cited by 260
Molecular imaging of the tumor microenvironment
Zhou, Z., & Lu, Z.-R. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.07.012 · Cited by 253
Self-citationXu, H., Yang, J., ZhuGe, D., Lin, M., Zhu, Q., Jin, B., Tong, M., Shen, B., Xiao, J., & Zhao, Y. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201701130 · Cited by 98
Harnessing Extracellular Matrix Biology for Tumor Drug Delivery
Subrahmanyam, N., & Ghandehari, H. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020088 · Cited by 42
Leveraging microenvironmental synthetic lethalities to treat cancer
Metcalf, K. J., Alazzeh, A., Werb, Z., & Weaver, V. M. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143765 · Cited by 42
Metadata
- Authors
- Zhou, Z., Qutaish, M., Han, Z., Schur, R. M., Liu, Y., Wilson, D. L., & Lu, Z.-R.
- Venue
- Nature Communications
- Published
- 2015-08-12
- Volume
- 6
- Issue
- 1
- Pages
- 7984-7984
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W1202879735
- Cited by
- 260
- References
- 49
- FWCI
- 9.59
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.